Esophagus, Phase III
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
Volunteers
Health Professionals
What is the purpose of this trial?
The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab.
The main objective Part 2 is to compare efficacy of bemarituzumab plus chemotherapy (mFOLFOX6 or capecitabine combined with oxaliplatin (CAPOX)) and nivolumab to placebo plus chemotherapy (mFOLFOX6 or CAPOX) and nivolumab as assessed by overall survival.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alison Johnson
- Andrea Brennan
- Armand Russo, MD
- Beverly Drucker, MD, PhD
- David Silverstone, MD
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Emily Kopas, APRN, OCN
- Gargi Khare Vora, MD
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jade Vanacore
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Jose Morales-Marin
- Justin Persico, MD
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Katelyn Scott
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Larisa Fleysher
- Laura Sabourin
- Laura Van Metre Baum, MD, MPH
- M. Sung Lee, MD
- Madeline Santiago
- Melissa Gambaccini
- Michael Cecchini, MD
- Michael Cohenuram, MD
- Michael Grant, MD
- Neal Fischbach, MD
- Pamela L. Kunz, MD
- Pawan Karanam, MD
- Renee Moye
- Sara Anastasio, RN
- Sharynn Hall, MD, PhD
- Stacey LaRosa
- Stacey Stein, MD
- Su Hsien Lim, MD
- Teresa White
- Vanna Dest
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Yifei Zhang, MD
- Zia Rahman, MD
- Last Updated07/22/2024
- Study HIC#2000034373